Idt (IDT) Holder American Century Companies Lowered Its Stake; As Foundation Medicine (FMI) Stock Value Rose, Platinum Investment Management LTD Has Cut by $2.57 Million Its Stake

May 18, 2018 - By Michael Collier

IDT Corporation (NYSE:IDT) Logo

American Century Companies Inc decreased its stake in Idt Corp (IDT) by 28.23% based on its latest 2017Q4 regulatory filing with the SEC. American Century Companies Inc sold 148,988 shares as the company’s stock declined 34.74% with the market. The institutional investor held 378,770 shares of the telecommunications equipment company at the end of 2017Q4, valued at $4.02M, down from 527,758 at the end of the previous reported quarter. American Century Companies Inc who had been investing in Idt Corp for a number of months, seems to be less bullish one the $131.48 million market cap company. The stock decreased 2.94% or $0.16 during the last trading session, reaching $5.29. About 28,790 shares traded. IDT Corporation (NYSE:IDT) has declined 45.16% since May 18, 2017 and is downtrending. It has underperformed by 56.71% the S&P500.

Kerr Neilson decreased its stake in Foundation Medicine Inc (FMI) by 41.68% based on its latest 2017Q4 regulatory filing with the SEC. Platinum Investment Management Ltd sold 37,800 shares as the company’s stock rose 20.73% while stock markets declined. The hedge fund run by Kerr Neilson held 52,900 shares of the health care company at the end of 2017Q4, valued at $3.61M, down from 90,700 at the end of the previous reported quarter. Platinum Investment Management Ltd who had been investing in Foundation Medicine Inc for a number of months, seems to be less bullish one the $3.00 billion market cap company. The stock increased 1.44% or $1.15 during the last trading session, reaching $80.9. About 87,951 shares traded. Foundation Medicine, Inc. (NASDAQ:FMI) has risen 134.36% since May 18, 2017 and is uptrending. It has outperformed by 122.81% the S&P500.

Platinum Investment Management Ltd, which manages about $22.00B and $3.77B US Long portfolio, upped its stake in Schlumberger Ltd (NYSE:SLB) by 268,100 shares to 1.82 million shares, valued at $122.43 million in 2017Q4, according to the filing. It also increased its holding in Gilead Sciences Inc (NASDAQ:GILD) by 145,300 shares in the quarter, for a total of 3.04M shares, and has risen its stake in Sina Corp (NASDAQ:SINA).

Investors sentiment increased to 1.39 in Q4 2017. Its up 0.11, from 1.28 in 2017Q3. It improved, as 13 investors sold FMI shares while 28 reduced holdings. 33 funds opened positions while 24 raised stakes. 10.07 million shares or 3.72% more from 9.71 million shares in 2017Q3 were reported. Raymond James And Assoc has invested 0% in Foundation Medicine, Inc. (NASDAQ:FMI). Legal & General Group Public Limited has 0% invested in Foundation Medicine, Inc. (NASDAQ:FMI) for 3,714 shares. Laurion Management Limited Partnership invested in 0% or 3,288 shares. Macquarie Grp Ltd has 102,808 shares for 0.01% of their portfolio. Thompson Davis And Co Inc, a Virginia-based fund reported 50 shares. Seabridge Investment Advsrs Limited Liability Corporation reported 0.01% in Foundation Medicine, Inc. (NASDAQ:FMI). Pier Capital Ltd holds 0.84% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 71,952 shares. Diker Ltd holds 0.29% in Foundation Medicine, Inc. (NASDAQ:FMI) or 12,000 shares. Principal Financial Inc reported 0% stake. Ameritas Invest Prtn Incorporated holds 0% or 1,258 shares in its portfolio. Wells Fargo And Company Mn accumulated 0% or 22,327 shares. Castleark Ltd Com has 19,540 shares for 0.04% of their portfolio. Aqr Capital Management Limited Liability Corp reported 0% in Foundation Medicine, Inc. (NASDAQ:FMI). Bamco holds 0.03% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 88,700 shares. Whittier invested 0.11% in Foundation Medicine, Inc. (NASDAQ:FMI).

Analysts await Foundation Medicine, Inc. (NASDAQ:FMI) to report earnings on August, 7. They expect $-1.11 EPS, up 10.48% or $0.13 from last year’s $-1.24 per share. After $-1.02 actual EPS reported by Foundation Medicine, Inc. for the previous quarter, Wall Street now forecasts 8.82% negative EPS growth.

More recent Foundation Medicine, Inc. (NASDAQ:FMI) news were published by: Seekingalpha.com which released: “Foundation Medicine’s (FMI) CEO Troy Cox on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018. Also Seekingalpha.com published the news titled: “Foundation’s new liquid biopsy test designated for accelerated review in US” on April 26, 2018. Businesswire.com‘s news article titled: “Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in China” with publication date: April 26, 2018 was also an interesting one.

Among 11 analysts covering Foundation Medicine (NASDAQ:FMI), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Foundation Medicine had 16 analyst reports since July 30, 2015 according to SRatingsIntel. Wells Fargo maintained Foundation Medicine, Inc. (NASDAQ:FMI) rating on Thursday, March 8. Wells Fargo has “Market Perform” rating and $80 target. The rating was upgraded by BTIG Research on Monday, May 15 to “Buy”. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) earned “Neutral” rating by BTIG Research on Wednesday, November 4. As per Thursday, November 3, the company rating was downgraded by Benchmark. The firm has “Market Perform” rating by JMP Securities given on Thursday, July 30. The firm has “Market Perform” rating given on Wednesday, September 16 by Wells Fargo. The stock has “Buy” rating by Cowen & Co on Wednesday, March 28. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) earned “Neutral” rating by Janney Capital on Tuesday, March 7. The stock has “Buy” rating by Cowen & Co on Thursday, February 15. The rating was initiated by BTIG Research on Monday, September 14 with “Buy”.

Investors sentiment decreased to 0.91 in 2017 Q4. Its down 0.16, from 1.07 in 2017Q3. It dived, as 20 investors sold IDT shares while 25 reduced holdings. 13 funds opened positions while 28 raised stakes. 11.48 million shares or 9.84% less from 12.73 million shares in 2017Q3 were reported. State Common Retirement Fund accumulated 17,600 shares or 0% of the stock. American Interest Grp Incorporated holds 0% or 11,718 shares. Parallax Volatility Advisers LP reported 2,646 shares. Royal Commercial Bank Of Canada owns 17,209 shares for 0% of their portfolio. New Jersey-based Prudential Inc has invested 0% in IDT Corporation (NYSE:IDT). First Manhattan invested in 66 shares. Foundry Prtn Lc invested in 0.19% or 435,295 shares. Blackrock holds 1.24 million shares. Credit Suisse Ag stated it has 0% in IDT Corporation (NYSE:IDT). Schwab Charles Inv Mngmt accumulated 78,386 shares or 0% of the stock. Federated Investors Pa holds 0% or 224 shares. Guggenheim Capital Limited Liability Corp accumulated 66,854 shares. Renaissance Techs Llc reported 1.34 million shares or 0.02% of all its holdings. Illinois-based Grp Inc One Trading LP has invested 0% in IDT Corporation (NYSE:IDT). Los Angeles Mngmt & Equity owns 50,814 shares.

American Century Companies Inc, which manages about $100.38B US Long portfolio, upped its stake in Global Brass & Coppr Hldgs I (NYSE:BRSS) by 76,735 shares to 1.02M shares, valued at $33.82M in 2017Q4, according to the filing. It also increased its holding in Zions Bancorporation (NASDAQ:ZION) by 136,198 shares in the quarter, for a total of 6.30 million shares, and has risen its stake in Compass Diversified Holdings (NYSE:CODI).

Since December 15, 2017, it had 1 buy, and 2 insider sales for $76,709 activity. COSENTINO ERIC F. sold $10,122 worth of stock.

More news for IDT Corporation (NYSE:IDT) were recently published by: Globenewswire.com, which released: “Factors of Influence in 2018, Key Indicators and Opportunity within IDT, National Presto Industries, EnPro Industries …” on May 17, 2018. Prnewswire.com‘s article titled: “NRS Launches Program to Help Bodega Owners Re-Design Stores for Success” and published on May 15, 2018 is yet another important article.

IDT Corporation (NYSE:IDT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>